Maze Therapeutics, Inc. MAZE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 700.00% | -88.06% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 700.00% | -88.06% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 700.00% | -88.06% | -- | -- | -- |
| SG&A Expenses | 43.16% | 38.90% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.05% | 31.33% | -- | -- | -- |
| Operating Income | -15.72% | -367.04% | -- | -- | -- |
| Income Before Tax | -10.09% | -330.73% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.59% | -335.93% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.59% | -335.93% | -- | -- | -- |
| EBIT | -15.72% | -367.04% | -- | -- | -- |
| EBITDA | -16.83% | -347.77% | -- | -- | -- |
| EPS Basic | 82.28% | -241.08% | -- | -- | -- |
| Normalized Basic EPS | 88.97% | -106.90% | -- | -- | -- |
| EPS Diluted | 82.61% | 63.67% | -- | -- | -- |
| Normalized Diluted EPS | 88.97% | -173.01% | -- | -- | -- |
| Average Basic Shares Outstanding | 174.44% | 448.75% | -- | -- | -- |
| Average Diluted Shares Outstanding | 174.44% | 404.85% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |